A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs
Patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant/intolerant to ≥2 tyrosine kinase inhibitors (TKIs) are at high risk of experiencing poor outcomes because of disease biology and inadequate efficacy and/or safety of current therapies. Asciminib, a first-in-class BCR-ABL1 inh...
Saved in:
| Published in | Blood Vol. 138; no. 21; pp. 2031 - 2041 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
25.11.2021
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant/intolerant to ≥2 tyrosine kinase inhibitors (TKIs) are at high risk of experiencing poor outcomes because of disease biology and inadequate efficacy and/or safety of current therapies. Asciminib, a first-in-class BCR-ABL1 inhibitor Specifically Targeting the ABL Myristoyl Pocket (STAMP), has the potential to overcome resistance/intolerance to approved TKIs. In this phase 3, open-label study, patients with CML-CP previously treated with ≥2 TKIs were randomized (2:1) to receive asciminib 40 mg twice daily vs bosutinib 500 mg once daily. Randomization was stratified by major cytogenetic response (MCyR) status at baseline. The primary objective was to compare the major molecular response (MMR) rate at week 24 for asciminib vs bosutinib. A total of 233 patients were randomized to asciminib (n = 157) or bosutinib (n = 76). Median follow-up was 14.9 months. The MMR rate at week 24 was 25.5% with asciminib and 13.2% with bosutinib. The difference in MMR rate between treatment arms, after adjusting for MCyR at baseline, was 12.2% (95% confidence interval, 2.19-22.30; 2-sided P = .029). Fewer grade ≥3 adverse events (50.6% vs 60.5%) and adverse events leading to treatment discontinuation (5.8% vs 21.1%) occurred with asciminib than with bosutinib. The study showed a superior efficacy of asciminib compared with that of bosutinib, together with a favorable safety profile. These results support the use of asciminib as a new therapy in patients with CML-CP who are resistant/intolerant to ≥2 prior TKIs. This trial was registered at www.clinicaltrials.gov as #NCT03106779.
•Asciminib demonstrated superior efficacy vs bosutinib and an improved safety profile in patients with CML-CP after at least 2 prior TKIs.•Asciminib has the potential to transform standard of care in this population through its novel mechanism of action as a STAMP inhibitor.
[Display omitted] |
|---|---|
| AbstractList | Patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant/intolerant to ≥2 tyrosine kinase inhibitors (TKIs) are at high risk of experiencing poor outcomes because of disease biology and inadequate efficacy and/or safety of current therapies. Asciminib, a first-in-class BCR-ABL1 inhibitor Specifically Targeting the ABL Myristoyl Pocket (STAMP), has the potential to overcome resistance/intolerance to approved TKIs. In this phase 3, open-label study, patients with CML-CP previously treated with ≥2 TKIs were randomized (2:1) to receive asciminib 40 mg twice daily vs bosutinib 500 mg once daily. Randomization was stratified by major cytogenetic response (MCyR) status at baseline. The primary objective was to compare the major molecular response (MMR) rate at week 24 for asciminib vs bosutinib. A total of 233 patients were randomized to asciminib (n = 157) or bosutinib (n = 76). Median follow-up was 14.9 months. The MMR rate at week 24 was 25.5% with asciminib and 13.2% with bosutinib. The difference in MMR rate between treatment arms, after adjusting for MCyR at baseline, was 12.2% (95% confidence interval, 2.19-22.30; 2-sided P = .029). Fewer grade ≥3 adverse events (50.6% vs 60.5%) and adverse events leading to treatment discontinuation (5.8% vs 21.1%) occurred with asciminib than with bosutinib. The study showed a superior efficacy of asciminib compared with that of bosutinib, together with a favorable safety profile. These results support the use of asciminib as a new therapy in patients with CML-CP who are resistant/intolerant to ≥2 prior TKIs. This trial was registered at www.clinicaltrials.gov as #NCT03106779.
•Asciminib demonstrated superior efficacy vs bosutinib and an improved safety profile in patients with CML-CP after at least 2 prior TKIs.•Asciminib has the potential to transform standard of care in this population through its novel mechanism of action as a STAMP inhibitor.
[Display omitted] Patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant/intolerant to ≥2 tyrosine kinase inhibitors (TKIs) are at high risk of experiencing poor outcomes because of disease biology and inadequate efficacy and/or safety of current therapies. Asciminib, a first-in-class BCR-ABL1 inhibitor Specifically Targeting the ABL Myristoyl Pocket (STAMP), has the potential to overcome resistance/intolerance to approved TKIs. In this phase 3, open-label study, patients with CML-CP previously treated with ≥2 TKIs were randomized (2:1) to receive asciminib 40 mg twice daily vs bosutinib 500 mg once daily. Randomization was stratified by major cytogenetic response (MCyR) status at baseline. The primary objective was to compare the major molecular response (MMR) rate at week 24 for asciminib vs bosutinib. A total of 233 patients were randomized to asciminib (n = 157) or bosutinib (n = 76). Median follow-up was 14.9 months. The MMR rate at week 24 was 25.5% with asciminib and 13.2% with bosutinib. The difference in MMR rate between treatment arms, after adjusting for MCyR at baseline, was 12.2% (95% confidence interval, 2.19-22.30; 2-sided P = .029). Fewer grade ≥3 adverse events (50.6% vs 60.5%) and adverse events leading to treatment discontinuation (5.8% vs 21.1%) occurred with asciminib than with bosutinib. The study showed a superior efficacy of asciminib compared with that of bosutinib, together with a favorable safety profile. These results support the use of asciminib as a new therapy in patients with CML-CP who are resistant/intolerant to ≥2 prior TKIs. This trial was registered at www.clinicaltrials.gov as #NCT03106779. Patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant/intolerant to ≥2 tyrosine kinase inhibitors (TKIs) are at high risk of experiencing poor outcomes because of disease biology and inadequate efficacy and/or safety of current therapies. Asciminib, a first-in-class BCR-ABL1 inhibitor Specifically Targeting the ABL Myristoyl Pocket (STAMP), has the potential to overcome resistance/intolerance to approved TKIs. In this phase 3, open-label study, patients with CML-CP previously treated with ≥2 TKIs were randomized (2:1) to receive asciminib 40 mg twice daily vs bosutinib 500 mg once daily. Randomization was stratified by major cytogenetic response (MCyR) status at baseline. The primary objective was to compare the major molecular response (MMR) rate at week 24 for asciminib vs bosutinib. A total of 233 patients were randomized to asciminib (n = 157) or bosutinib (n = 76). Median follow-up was 14.9 months. The MMR rate at week 24 was 25.5% with asciminib and 13.2% with bosutinib. The difference in MMR rate between treatment arms, after adjusting for MCyR at baseline, was 12.2% (95% confidence interval, 2.19-22.30; 2-sided P = .029). Fewer grade ≥3 adverse events (50.6% vs 60.5%) and adverse events leading to treatment discontinuation (5.8% vs 21.1%) occurred with asciminib than with bosutinib. The study showed a superior efficacy of asciminib compared with that of bosutinib, together with a favorable safety profile. These results support the use of asciminib as a new therapy in patients with CML-CP who are resistant/intolerant to ≥2 prior TKIs. This trial was registered at www.clinicaltrials.gov as #NCT03106779.Patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant/intolerant to ≥2 tyrosine kinase inhibitors (TKIs) are at high risk of experiencing poor outcomes because of disease biology and inadequate efficacy and/or safety of current therapies. Asciminib, a first-in-class BCR-ABL1 inhibitor Specifically Targeting the ABL Myristoyl Pocket (STAMP), has the potential to overcome resistance/intolerance to approved TKIs. In this phase 3, open-label study, patients with CML-CP previously treated with ≥2 TKIs were randomized (2:1) to receive asciminib 40 mg twice daily vs bosutinib 500 mg once daily. Randomization was stratified by major cytogenetic response (MCyR) status at baseline. The primary objective was to compare the major molecular response (MMR) rate at week 24 for asciminib vs bosutinib. A total of 233 patients were randomized to asciminib (n = 157) or bosutinib (n = 76). Median follow-up was 14.9 months. The MMR rate at week 24 was 25.5% with asciminib and 13.2% with bosutinib. The difference in MMR rate between treatment arms, after adjusting for MCyR at baseline, was 12.2% (95% confidence interval, 2.19-22.30; 2-sided P = .029). Fewer grade ≥3 adverse events (50.6% vs 60.5%) and adverse events leading to treatment discontinuation (5.8% vs 21.1%) occurred with asciminib than with bosutinib. The study showed a superior efficacy of asciminib compared with that of bosutinib, together with a favorable safety profile. These results support the use of asciminib as a new therapy in patients with CML-CP who are resistant/intolerant to ≥2 prior TKIs. This trial was registered at www.clinicaltrials.gov as #NCT03106779. |
| Author | Minami, Yosuke Voloshin, Sergey Kim, Dennis Dong Hwan Turkina, Anna Bédoucha, Véronique Fogliatto, Laura Maria Cortes, Jorge E. Lomaia, Elza Annunziata, Mario Kim, Dong-Wook Aimone, Paola Sasaki, Koji Boquimpani, Carla Quenet, Sara Abdo, Andre Chee, Lynette Mauro, Michael J. Apperley, Jane F. Chaudhri, Naeem Réa, Delphine García-Gutiérrez, Valentin Saussele, Susanne Hochhaus, Andreas Allepuz, Alex le Coutre, Philipp Hughes, Timothy P. |
| Author_xml | – sequence: 1 givenname: Delphine orcidid: 0000-0001-5379-7461 surname: Réa fullname: Réa, Delphine email: delphine.rea@aphp.fr organization: DMU Hématologie, Hôpital Saint-Louis, Paris, France – sequence: 2 givenname: Michael J. orcidid: 0000-0002-2251-4032 surname: Mauro fullname: Mauro, Michael J. organization: Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York, NY – sequence: 3 givenname: Carla surname: Boquimpani fullname: Boquimpani, Carla organization: HEMORIO, State Institute of Hematology Arthur de Siquiera Cavalcanti, Rio de Janeiro, Brazil – sequence: 4 givenname: Yosuke surname: Minami fullname: Minami, Yosuke organization: Department of Hematology, National Cancer Center Hospital East, Kashiwa, Japan – sequence: 5 givenname: Elza orcidid: 0000-0003-3290-7961 surname: Lomaia fullname: Lomaia, Elza organization: Institute of Oncology and Hematology, Almazov National Medical Research Centre, St Petersburg, Russia – sequence: 6 givenname: Sergey orcidid: 0000-0003-1784-0375 surname: Voloshin fullname: Voloshin, Sergey organization: Hematology and Bone Marrow Transplantation, Russian Research Institute of Hematology and Transfusiology, St Petersburg, Russia – sequence: 7 givenname: Anna surname: Turkina fullname: Turkina, Anna organization: Scientific and Advisory Department of Hemotherapy of Myeloproliferative Disorders, National Research Center for Hematology, Moscow, Russia – sequence: 8 givenname: Dong-Wook surname: Kim fullname: Kim, Dong-Wook organization: Hematologic Tumor Medicine Department, Uijeongbu Eulji Medical Center, Eulji University, Uijeongbu, South Korea – sequence: 9 givenname: Jane F. orcidid: 0000-0002-1710-1794 surname: Apperley fullname: Apperley, Jane F. organization: Department of Immunology and Inflammation, Centre for Haematology Imperial College London, London, United Kingdom – sequence: 10 givenname: Andre orcidid: 0000-0002-7486-3525 surname: Abdo fullname: Abdo, Andre organization: Hemato-Oncology Department, Instituto do Câncer do Estado de São Paulo (ICESPSP), São Paulo, Brazil – sequence: 11 givenname: Laura Maria surname: Fogliatto fullname: Fogliatto, Laura Maria organization: Hematology and Hemotherapy Department, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Brazil – sequence: 12 givenname: Dennis Dong Hwan surname: Kim fullname: Kim, Dennis Dong Hwan organization: Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada – sequence: 13 givenname: Philipp surname: le Coutre fullname: le Coutre, Philipp organization: Department of Oncology and Hematology, Charité–Universitätsmedizin Berlin, Berlin, Germany – sequence: 14 givenname: Susanne orcidid: 0000-0003-0357-5785 surname: Saussele fullname: Saussele, Susanne organization: Department of Haematology and Oncology, III. Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany – sequence: 15 givenname: Mario orcidid: 0000-0001-9993-947X surname: Annunziata fullname: Annunziata, Mario organization: Division of Hematology, AORN Cardarelli, Naples, Italy – sequence: 16 givenname: Timothy P. surname: Hughes fullname: Hughes, Timothy P. organization: South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, Australia – sequence: 17 givenname: Naeem orcidid: 0000-0001-8623-1798 surname: Chaudhri fullname: Chaudhri, Naeem organization: Hematology, Stem Cell Transplant and Cellular Therapy Section, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia – sequence: 18 givenname: Koji orcidid: 0000-0002-9140-0610 surname: Sasaki fullname: Sasaki, Koji organization: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX – sequence: 19 givenname: Lynette orcidid: 0000-0002-4250-4448 surname: Chee fullname: Chee, Lynette organization: Haematology Department, Peter MacCallum Cancer Center–The Royal Melbourne Hospital, Melbourne, Australia – sequence: 20 givenname: Valentin orcidid: 0000-0003-4752-0815 surname: García-Gutiérrez fullname: García-Gutiérrez, Valentin organization: Servicio de Hematología, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain – sequence: 21 givenname: Jorge E. surname: Cortes fullname: Cortes, Jorge E. organization: Georgia Cancer Center, Augusta, GA – sequence: 22 givenname: Paola surname: Aimone fullname: Aimone, Paola organization: Novartis Pharma AG, Basel, Switzerland – sequence: 23 givenname: Alex surname: Allepuz fullname: Allepuz, Alex organization: Novartis Pharma AG, Basel, Switzerland – sequence: 24 givenname: Sara surname: Quenet fullname: Quenet, Sara organization: Novartis Pharma AG, Basel, Switzerland – sequence: 25 givenname: Véronique surname: Bédoucha fullname: Bédoucha, Véronique organization: Novartis Pharma AG, Basel, Switzerland – sequence: 26 givenname: Andreas surname: Hochhaus fullname: Hochhaus, Andreas organization: Department of Hematology and Internal Oncology, Universitätsklinikum Jena, Jena, Germany |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34407542$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kc1rFDEchoNU7LZ69yQ5etip-ZqZxNuy-FHcouB6Dvn4DY3MTNYk01L_elO3Kgh6Snh5nhDe9wydzHEGhJ5TckGpZK_sGKO_YIQRQpSS4hFa0ZbJhtTkBK1q2jVC9fQUneX8lRAqOGufoFMuBOlbwVbodoMP1yYD5mscDzA3o7EwrnEys49T-A4e57L4OxwHbLILU5iDXWODP-83V59wmK-DDSWmNb7J2Ma8lHug5nh7tcNmKJAwwzHhKSbAhxTqdf_hMj9FjwczZnj2cJ6jL2_f7Lfvm93Hd5fbza5xopWlcVwJ11nHfd8bz5VTg3Oug06ZVlFuLXWgTG9aymRH-0EqKxmVhngFRAjg5-jl8d1Dit8WyEVPITsYRzNDXLJmbcckp5Wt6IsHdLETeF0_O5l0p3-VVQFyBFyKOScYfiOU6Ps99M899J89qtL9pbhQTAlxLsmE8X_i66MItZybAEnX8mF24EMCV7SP4d_yD0trodQ |
| CitedBy_id | crossref_primary_10_1002_hon_2987 crossref_primary_10_1016_j_ejps_2023_106678 crossref_primary_10_3390_ijms231911836 crossref_primary_10_1007_s00044_022_03011_9 crossref_primary_10_1007_s11899_022_00679_z crossref_primary_10_1182_blood_2024025800 crossref_primary_10_3390_ijms222112089 crossref_primary_10_5124_jkma_2023_66_4_224 crossref_primary_10_1007_s12185_022_03446_1 crossref_primary_10_1002_mco2_181 crossref_primary_10_4254_wjh_v15_i9_1021 crossref_primary_10_1111_cts_13285 crossref_primary_10_2217_fon_2021_1174 crossref_primary_10_1016_j_bulcan_2023_10_010 crossref_primary_10_1007_s12185_024_03805_0 crossref_primary_10_5045_br_2023_2023054 crossref_primary_10_1186_s13045_022_01309_0 crossref_primary_10_3390_biom14060644 crossref_primary_10_1002_ajh_26642 crossref_primary_10_1038_s41375_024_02159_0 crossref_primary_10_3390_cancers15164161 crossref_primary_10_1172_JCI154943 crossref_primary_10_1007_s11899_024_00728_9 crossref_primary_10_2217_fon_2023_0095 crossref_primary_10_1038_s41375_024_02411_7 crossref_primary_10_4103_ijciis_ijciis_85_22 crossref_primary_10_3389_fonc_2024_1369246 crossref_primary_10_1007_s00277_025_06238_9 crossref_primary_10_1002_ajh_27443 crossref_primary_10_5194_mr_3_91_2022 crossref_primary_10_1007_s12185_022_03431_8 crossref_primary_10_1093_ajhp_zxac286 crossref_primary_10_1371_journal_pone_0294438 crossref_primary_10_1016_j_blre_2024_101196 crossref_primary_10_1016_S2352_3026_23_00164_3 crossref_primary_10_1182_blood_2021013257 crossref_primary_10_3389_fonc_2021_801779 crossref_primary_10_1002_cpdd_1019 crossref_primary_10_1016_j_clml_2024_10_010 crossref_primary_10_1038_s41408_023_00823_9 crossref_primary_10_1158_1078_0432_CCR_24_1086 crossref_primary_10_3390_hemato4030020 crossref_primary_10_1038_s41375_023_01940_x crossref_primary_10_2217_fon_2022_0923 crossref_primary_10_1016_S2152_2650_24_00381_1 crossref_primary_10_3390_cancers15041045 crossref_primary_10_1007_s11899_023_00703_w crossref_primary_10_3390_ijms25063307 crossref_primary_10_4264_numa_81_4_193 crossref_primary_10_3390_cancers14102533 crossref_primary_10_1016_j_drudis_2024_104115 crossref_primary_10_1186_s13045_024_01642_6 crossref_primary_10_3324_haematol_2022_281493 crossref_primary_10_3389_fonc_2024_1455378 crossref_primary_10_1002_ccr3_6478 crossref_primary_10_1080_17474086_2022_2080049 crossref_primary_10_1002_cpt_2699 crossref_primary_10_1080_10428194_2024_2342559 crossref_primary_10_1007_s00277_024_05906_6 crossref_primary_10_1182_bloodadvances_2023012127 crossref_primary_10_1007_s00210_022_02250_2 crossref_primary_10_1016_j_bulcan_2022_04_003 crossref_primary_10_1007_s40495_023_00316_0 crossref_primary_10_1007_s11864_023_01149_1 crossref_primary_10_1038_s41408_025_01242_8 crossref_primary_10_1007_s12185_025_03944_y crossref_primary_10_1080_14740338_2024_2331190 crossref_primary_10_3987_COM_23_14824 crossref_primary_10_1016_j_banm_2023_04_005 crossref_primary_10_1182_bloodadvances_2024012655 crossref_primary_10_1111_ejh_14330 crossref_primary_10_3389_fonc_2022_1036437 crossref_primary_10_1017_pcm_2023_9 crossref_primary_10_7554_eLife_92324 crossref_primary_10_1038_s41375_023_01888_y crossref_primary_10_1038_s41375_023_01822_2 crossref_primary_10_3389_fonc_2024_1446517 crossref_primary_10_1016_j_ejmech_2022_114898 crossref_primary_10_1002_ajh_26695 crossref_primary_10_1002_ange_202117276 crossref_primary_10_1007_s12185_022_03432_7 crossref_primary_10_1016_j_bulcan_2022_10_006 crossref_primary_10_1016_j_medj_2024_11_003 crossref_primary_10_1080_13696998_2023_2234776 crossref_primary_10_1080_14796694_2024_2402680 crossref_primary_10_1080_14796694_2025_2464494 crossref_primary_10_1111_cts_13252 crossref_primary_10_3390_cancers14030620 crossref_primary_10_1002_ajh_26852 crossref_primary_10_1182_blood_2021014689 crossref_primary_10_1007_s12185_024_03873_2 crossref_primary_10_1038_s41375_024_02372_x crossref_primary_10_1001_jamaoncol_2023_2306 crossref_primary_10_3389_fphar_2023_1261312 crossref_primary_10_1002_cncr_35737 crossref_primary_10_1007_s00761_024_01663_3 crossref_primary_10_1016_j_medj_2024_07_001 crossref_primary_10_1002_anie_202117276 crossref_primary_10_1016_j_clml_2024_09_013 crossref_primary_10_1016_j_leukres_2024_107481 crossref_primary_10_1016_S2352_3026_23_00088_1 crossref_primary_10_1254_fpj_22156 crossref_primary_10_58931_cht_2024_3253 crossref_primary_10_21320_2500_2139_2023_16_1_54_68 crossref_primary_10_3390_ijms25021201 crossref_primary_10_1007_s00262_022_03361_8 crossref_primary_10_1016_j_leukres_2023_107374 crossref_primary_10_1038_s41375_024_02278_8 crossref_primary_10_1158_1078_0432_CCR_22_2628 crossref_primary_10_5045_br_2023_2023017 crossref_primary_10_3389_fonc_2024_1405467 crossref_primary_10_1200_JCO_23_00897 crossref_primary_10_1155_2023_2004135 crossref_primary_10_1182_blood_2023022403 crossref_primary_10_1021_acs_jmedchem_2c00373 crossref_primary_10_1038_s41375_023_01829_9 crossref_primary_10_1002_cam4_5212 crossref_primary_10_1111_imj_16446 crossref_primary_10_1002_ajh_26686 crossref_primary_10_1080_17474086_2021_1990034 crossref_primary_10_1038_s41467_023_38732_x crossref_primary_10_1007_s11899_022_00683_3 crossref_primary_10_1016_S2352_3026_22_00246_0 crossref_primary_10_1038_s41408_023_00891_x crossref_primary_10_1177_10732748241285755 crossref_primary_10_1007_s12185_024_03816_x crossref_primary_10_1007_s00432_022_04562_5 crossref_primary_10_21518_ms2023_362 crossref_primary_10_1007_s11886_023_01845_2 crossref_primary_10_1159_000540542 crossref_primary_10_1038_s41375_023_01860_w crossref_primary_10_1007_s11912_024_01502_z crossref_primary_10_1038_s41392_024_01759_7 crossref_primary_10_2147_BLCTT_S219160 crossref_primary_10_1038_s41375_024_02229_3 crossref_primary_10_3390_cancers14071805 crossref_primary_10_1007_s11010_022_04376_6 crossref_primary_10_1111_bjh_18323 crossref_primary_10_1016_j_bmcl_2022_128577 crossref_primary_10_1002_prp2_1214 crossref_primary_10_1016_S2352_3026_24_00354_5 crossref_primary_10_1038_s41375_022_01736_5 crossref_primary_10_1182_blood_2023022538 crossref_primary_10_1002_cpdd_1213 crossref_primary_10_1007_s12185_022_03526_2 crossref_primary_10_3390_ijms241813806 crossref_primary_10_1001_jamanetworkopen_2024_14425 crossref_primary_10_12677_acm_2024_14102826 crossref_primary_10_1002_ajh_27355 crossref_primary_10_3389_fonc_2022_1021662 crossref_primary_10_1182_hematology_2022000328 crossref_primary_10_2174_1570178620666221026095145 crossref_primary_10_3390_cancers16112114 crossref_primary_10_1007_s40262_024_01428_6 crossref_primary_10_1016_j_clml_2023_12_011 crossref_primary_10_1073_pnas_2304611120 crossref_primary_10_1111_cts_70053 crossref_primary_10_1182_blood_2024024657 crossref_primary_10_1177_10781552231173441 crossref_primary_10_2174_1568009622666220613144253 crossref_primary_10_1021_acs_jmedchem_2c00030 crossref_primary_10_1080_17474086_2022_2142112 crossref_primary_10_1016_j_clml_2024_01_005 crossref_primary_10_1182_hematology_2022000329 crossref_primary_10_1007_s11899_022_00673_5 crossref_primary_10_1007_s00761_022_01290_w crossref_primary_10_1002_cncr_34619 crossref_primary_10_1002_cbin_70007 crossref_primary_10_1038_s41409_023_01975_9 crossref_primary_10_1007_s00280_025_04755_y crossref_primary_10_1111_bcp_16381 crossref_primary_10_1007_s40265_021_01662_3 crossref_primary_10_3324_haematol_2022_281386 crossref_primary_10_1080_14656566_2022_2064742 crossref_primary_10_3390_cancers17010092 crossref_primary_10_1007_s00277_024_05851_4 crossref_primary_10_1007_s12012_023_09800_x crossref_primary_10_7554_eLife_92324_3 crossref_primary_10_1056_NEJMoa2400858 crossref_primary_10_1080_14656566_2023_2240702 crossref_primary_10_1007_s11864_023_01088_x crossref_primary_10_1016_j_clml_2023_12_007 crossref_primary_10_2147_CMAR_S353374 crossref_primary_10_1038_s41375_023_02122_5 crossref_primary_10_1177_20406207221150305 crossref_primary_10_1016_j_ejmech_2024_116441 crossref_primary_10_1002_mog2_69 crossref_primary_10_1080_17474086_2022_2077187 crossref_primary_10_2174_1574892818666230111115040 crossref_primary_10_3324_haematol_2022_282361 crossref_primary_10_1080_17474086_2024_2440776 |
| Cites_doi | 10.1038/s41375-020-0776-2 10.1182/blood-2009-05-221531 10.1002/ajh.24536 10.1182/blood-2011-11-390120 10.1182/blood-2016-01-694265 10.1016/j.clml.2018.06.029 10.1016/j.hoc.2011.09.004 10.1200/JCO.2013.49.9020 10.1002/ajh.25342 10.1016/j.clml.2015.03.006 10.1021/acs.jmedchem.8b01040 10.1177/2040620719826444 10.3324/haematol.2013.095158 10.1038/s41375-020-0915-9 10.1002/ajh.23728 10.1182/blood-2016-09-739086 10.1182/blood-2013-05-501569 10.1002/ajh.23973 10.1038/s41375-020-0842-9 10.1038/leu.2017.253 10.1038/leu.2012.181 10.1038/leu.2015.152 10.1016/S2352-3026(15)00048-4 10.1056/NEJMoa1902328 10.1158/0008-5472.CAN-12-1276 10.1038/nature21702 10.1200/JCO.2011.38.7522 10.1002/ajh.24423 10.1200/JCO.2017.74.7162 10.1016/j.hoc.2017.04.007 10.1016/j.leukres.2020.106458 10.1016/j.ccell.2019.08.004 |
| ContentType | Journal Article |
| Copyright | 2021 American Society of Hematology 2021 by The American Society of Hematology. |
| Copyright_xml | – notice: 2021 American Society of Hematology – notice: 2021 by The American Society of Hematology. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1182/blood.2020009984 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Chemistry Biology Anatomy & Physiology |
| EISSN | 1528-0020 |
| EndPage | 2041 |
| ExternalDocumentID | 34407542 10_1182_blood_2020009984 S0006497121014762 |
| Genre | Clinical Trial, Phase III Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: P30 CA008748 |
| GroupedDBID | --- -~X .55 1CY 23N 2WC 34G 39C 4.4 53G 5GY 5RE 5VS 6J9 AAEDW AAXUO ABOCM ABVKL ACGFO ADBBV AENEX AFOSN AHPSJ ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BTFSW CS3 DIK DU5 E3Z EBS EJD EX3 F5P FDB FRP GS5 GX1 IH2 K-O KQ8 L7B LSO MJL N9A OK1 P2P R.V RHF RHI ROL SJN THE TR2 TWZ W2D W8F WH7 WOQ WOW X7M YHG YKV ZA5 0R~ AALRI AAYXX ACVFH ADCNI ADVLN AEUPX AFETI AFPUW AGCQF AIGII AITUG AKBMS AKRWK AKYEP CITATION H13 CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c458t-c394c6bc3d77ad39c9fccc6e69a5913bb1ce9a7a5128617f89b8218a0d9e044e3 |
| ISSN | 0006-4971 1528-0020 |
| IngestDate | Fri Jul 11 01:13:25 EDT 2025 Wed Feb 19 02:25:23 EST 2025 Thu Apr 24 22:52:06 EDT 2025 Tue Jul 01 00:19:43 EDT 2025 Fri Feb 23 02:41:16 EST 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 21 |
| Language | English |
| License | 2021 by The American Society of Hematology. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c458t-c394c6bc3d77ad39c9fccc6e69a5913bb1ce9a7a5128617f89b8218a0d9e044e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0001-8623-1798 0000-0003-3290-7961 0000-0003-0357-5785 0000-0002-1710-1794 0000-0002-2251-4032 0000-0002-7486-3525 0000-0001-9993-947X 0000-0001-5379-7461 0000-0003-4752-0815 0000-0003-1784-0375 0000-0002-4250-4448 0000-0002-9140-0610 |
| OpenAccessLink | https://ashpublications.org/blood/article-pdf/138/21/2031/1847923/bloodbld2020009984.pdf |
| PMID | 34407542 |
| PQID | 2562831044 |
| PQPubID | 23479 |
| PageCount | 11 |
| ParticipantIDs | proquest_miscellaneous_2562831044 pubmed_primary_34407542 crossref_primary_10_1182_blood_2020009984 crossref_citationtrail_10_1182_blood_2020009984 elsevier_sciencedirect_doi_10_1182_blood_2020009984 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-11-25 20211125 |
| PublicationDateYYYYMMDD | 2021-11-25 |
| PublicationDate_xml | – month: 11 year: 2021 text: 2021-11-25 day: 25 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Blood |
| PublicationTitleAlternate | Blood |
| PublicationYear | 2021 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Baccarani, Deininger, Rosti (bib24) 2013; 122 García-Gutiérrez, Martinez-Trillos, Lopez Lorenzo (bib26) 2015; 90 Hochhaus, Breccia, Saglio (bib10) 2020; 34 Cortes, Rea, Lipton (bib3) 2019; 94 Gambacorti-Passerini, Brümmendorf, Kim (bib25) 2014; 89 Hehlmann, Lauseker, Saußele (bib27) 2017; 31 Cortes, Kim, Pinilla-Ibarz (bib14) 2018; 132 Manley, Barys, Cowan-Jacob (bib17) 2020; 98 Hehlmann, Müller, Lauseker (bib33) 2014; 32 Hantschel, Grebien, Superti-Furga (bib19) 2012; 72 Hughes, Mauro, Cortes (bib18) 2019; 381 Schoepfer, Jahnke, Berellini (bib15) 2018; 61 Cortes, Gambacorti-Passerini, Deininger (bib34) 2018; 36 National Comprehensive Cancer Network,. NCCN: Clinical Practice Guidelines in Oncology. Chronic Myeloid Leukemia V3.2021. Jabbour, Parikh, Kantarjian, Cortes (bib6) 2011; 25 Hochhaus, Gambacorti-Passerini, Abboud, BYOND Study Investigators (bib31) 2020; 34 Garg, Kantarjian, O'Brien (bib13) 2009; 114 Molica, Scalzulli, Colafigli, Foà, Breccia (bib23) 2019; 10 Castagnetti, Gugliotta, Breccia, GIMEMA CML Working Party (bib28) 2015; 29 Cortes, Kim, Kantarjian (bib35) 2012; 30 Sasaki, Strom, O'Brien (bib5) 2015; 2 Khoury, Cortes, Kantarjian (bib11) 2012; 119 Wylie, Schoepfer, Jahnke (bib16) 2017; 543 Etienne, Dulucq, Nicolini (bib32) 2014; 99 Cortes, Lomaia, Turkina (bib22) 2020; 38 Hochhaus, Baccarani, Silver (bib4) 2020; 34 Hughes, Ross (bib2) 2016; 128 Jabbour, Kantarjian, Cortes (bib9) 2015; 15 Giles, le Coutre, Pinilla-Ibarz (bib30) 2013; 27 Patel, O'Hare, Deininger (bib7) 2017; 31 Bosulif (bosutinib). New York, NY: Pfizer, Inc.; 2020. Shah, Rousselot, Schiffer (bib29) 2016; 91 Eide, Zabriskie, Savage Stevens (bib36) 2019; 36 Chopade, Akard (bib1) 2018; 18 Cortes, Khoury, Kantarjian (bib12) 2016; 91 Bosulif (bosutinib) [summary of product characteristics]., Brussels, Belgium: Pfizer Europe; 2020. Hehlmann (2021112516212598700_B27) 2017; 31 Hochhaus (2021112516212598700_B10) 2020; 34 Wylie (2021112516212598700_B16) 2017; 543 Baccarani (2021112516212598700_B24) 2013; 122 Hughes (2021112516212598700_B2) 2016; 128 Sasaki (2021112516212598700_B5) 2015; 2 Cortes (2021112516212598700_B14) 2018; 132 Hantschel (2021112516212598700_B19) 2012; 72 Hochhaus (2021112516212598700_B31) 2020; 34 Eide (2021112516212598700_B36) 2019; 36 Garg (2021112516212598700_B13) 2009; 114 (2021112516212598700_B20) 2020 Cortes (2021112516212598700_B34) 2018; 36 Manley (2021112516212598700_B17) 2020; 98 García-Gutiérrez (2021112516212598700_B26) 2015; 90 Castagnetti (2021112516212598700_B28) 2015; 29 Etienne (2021112516212598700_B32) 2014; 99 Cortes (2021112516212598700_B22) 2020; 38 Molica (2021112516212598700_B23) 2019; 10 Cortes (2021112516212598700_B35) 2012; 30 Jabbour (2021112516212598700_B9) 2015; 15 Jabbour (2021112516212598700_B6) 2011; 25 Giles (2021112516212598700_B30) 2013; 27 Khoury (2021112516212598700_B11) 2012; 119 (2021112516212598700_B21) 2020 Schoepfer (2021112516212598700_B15) 2018; 61 Chopade (2021112516212598700_B1) 2018; 18 Hughes (2021112516212598700_B18) 2019; 381 Cortes (2021112516212598700_B3) 2019; 94 Hochhaus (2021112516212598700_B4) 2020; 34 Cortes (2021112516212598700_B12) 2016; 91 Shah (2021112516212598700_B29) 2016; 91 Patel (2021112516212598700_B7) 2017; 31 Hehlmann (2021112516212598700_B33) 2014; 32 Gambacorti-Passerini (2021112516212598700_B25) 2014; 89 National Comprehensive Cancer Network (2021112516212598700_B8) 34821938 - Blood. 2021 Nov 25;138(21):2009-2010 |
| References_xml | – volume: 31 start-page: 589 year: 2017 end-page: 612 ident: bib7 article-title: Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors publication-title: Hematol Oncol Clin North Am. – volume: 15 start-page: 323 year: 2015 end-page: 334 ident: bib9 article-title: Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm publication-title: Clin Lymphoma Myeloma Leuk. – volume: 89 start-page: 732 year: 2014 end-page: 742 ident: bib25 article-title: Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: minimum 24-month follow-up publication-title: Am J Hematol. – reference: National Comprehensive Cancer Network,. NCCN: Clinical Practice Guidelines in Oncology. Chronic Myeloid Leukemia V3.2021. – volume: 61 start-page: 8120 year: 2018 end-page: 8135 ident: bib15 article-title: Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1 publication-title: J Med Chem. – volume: 543 start-page: 733 year: 2017 end-page: 737 ident: bib16 article-title: The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1 publication-title: Nature. – volume: 2 start-page: e186 year: 2015 end-page: e193 ident: bib5 article-title: Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials publication-title: Lancet Haematol. – volume: 91 start-page: 1206 year: 2016 end-page: 1214 ident: bib12 article-title: Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib publication-title: Am J Hematol. – volume: 31 start-page: 2398 year: 2017 end-page: 2406 ident: bib27 article-title: Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants publication-title: Leukemia. – volume: 25 start-page: 981 year: 2011 end-page: 995 ident: bib6 article-title: Chronic myeloid leukemia: mechanisms of resistance and treatment publication-title: Hematol Oncol Clin North Am. – reference: Bosulif (bosutinib) [summary of product characteristics]., Brussels, Belgium: Pfizer Europe; 2020. – volume: 29 start-page: 1823 year: 2015 end-page: 1831 ident: bib28 article-title: Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib publication-title: Leukemia. – volume: 99 start-page: 458 year: 2014 end-page: 464 ident: bib32 article-title: Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy publication-title: Haematologica. – volume: 30 start-page: 3486 year: 2012 end-page: 3492 ident: bib35 article-title: Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial publication-title: J Clin Oncol. – volume: 128 start-page: 17 year: 2016 end-page: 23 ident: bib2 article-title: Moving treatment-free remission into mainstream clinical practice in CML publication-title: Blood. – volume: 36 start-page: 231 year: 2018 end-page: 237 ident: bib34 article-title: Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE Trial publication-title: J Clin Oncol. – volume: 119 start-page: 3403 year: 2012 end-page: 3412 ident: bib11 article-title: Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure publication-title: Blood. – volume: 114 start-page: 4361 year: 2009 end-page: 4368 ident: bib13 article-title: The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up publication-title: Blood. – volume: 132 start-page: 393 year: 2018 end-page: 404 ident: bib14 article-title: Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial publication-title: Blood. – volume: 122 start-page: 872 year: 2013 end-page: 884 ident: bib24 article-title: European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 publication-title: Blood. – volume: 94 start-page: 346 year: 2019 end-page: 357 ident: bib3 article-title: Treatment-free remission with first- and second-generation tyrosine kinase inhibitors publication-title: Am J Hematol. – volume: 34 start-page: 966 year: 2020 end-page: 984 ident: bib4 article-title: European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia publication-title: Leukemia. – volume: 98 start-page: 106458 year: 2020 ident: bib17 article-title: The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase publication-title: Leuk Res. – volume: 90 start-page: 429 year: 2015 end-page: 433 ident: bib26 article-title: Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program publication-title: Am J Hematol. – volume: 91 start-page: 869 year: 2016 end-page: 874 ident: bib29 article-title: Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034 publication-title: Am J Hematol. – volume: 32 start-page: 415 year: 2014 end-page: 423 ident: bib33 article-title: Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV publication-title: J Clin Oncol. – volume: 36 start-page: 431 year: 2019 end-page: 443.e5 ident: bib36 article-title: Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants publication-title: Cancer Cell. – volume: 38 year: 2020 ident: bib22 article-title: Interim analysis (IA) of OPTIC: a dose-ranging study of three ponatinib (PON) starting doses publication-title: . – volume: 34 start-page: 2125 year: 2020 end-page: 2137 ident: bib31 article-title: Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study publication-title: Leukemia. – volume: 72 start-page: 4890 year: 2012 end-page: 4895 ident: bib19 article-title: The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL publication-title: Cancer Res. – volume: 27 start-page: 107 year: 2013 end-page: 112 ident: bib30 article-title: Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study publication-title: Leukemia. – volume: 10 start-page: 6444 year: 2019 ident: bib23 article-title: Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia publication-title: Ther Adv Hematol. – volume: 18 start-page: 710 year: 2018 end-page: 723 ident: bib1 article-title: Improving outcomes in chronic myeloid leukemia over time in the era of tyrosine kinase inhibitors publication-title: Clin Lymphoma Myeloma Leuk. – reference: Bosulif (bosutinib). New York, NY: Pfizer, Inc.; 2020. – volume: 381 start-page: 2315 year: 2019 end-page: 2326 ident: bib18 article-title: Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure publication-title: N Engl J Med. – volume: 34 start-page: 1495 year: 2020 end-page: 1502 ident: bib10 article-title: Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors publication-title: Leukemia. – volume: 34 start-page: 966 issue: 4 year: 2020 ident: 2021112516212598700_B4 article-title: European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia publication-title: Leukemia. doi: 10.1038/s41375-020-0776-2 – volume: 38 issue: 15 year: 2020 ident: 2021112516212598700_B22 article-title: Interim analysis (IA) of OPTIC: a dose-ranging study of three ponatinib (PON) starting doses publication-title: J Clin Oncol. – volume: 114 start-page: 4361 issue: 20 year: 2009 ident: 2021112516212598700_B13 article-title: The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up publication-title: Blood. doi: 10.1182/blood-2009-05-221531 – volume: 91 start-page: 1206 issue: 12 year: 2016 ident: 2021112516212598700_B12 article-title: Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib publication-title: Am J Hematol. doi: 10.1002/ajh.24536 – volume: 119 start-page: 3403 issue: 15 year: 2012 ident: 2021112516212598700_B11 article-title: Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure publication-title: Blood. doi: 10.1182/blood-2011-11-390120 – volume: 128 start-page: 17 issue: 1 year: 2016 ident: 2021112516212598700_B2 article-title: Moving treatment-free remission into mainstream clinical practice in CML publication-title: Blood. doi: 10.1182/blood-2016-01-694265 – volume: 18 start-page: 710 issue: 11 year: 2018 ident: 2021112516212598700_B1 article-title: Improving outcomes in chronic myeloid leukemia over time in the era of tyrosine kinase inhibitors publication-title: Clin Lymphoma Myeloma Leuk. doi: 10.1016/j.clml.2018.06.029 – volume: 25 start-page: 981 issue: 5 year: 2011 ident: 2021112516212598700_B6 article-title: Chronic myeloid leukemia: mechanisms of resistance and treatment publication-title: Hematol Oncol Clin North Am. doi: 10.1016/j.hoc.2011.09.004 – volume: 32 start-page: 415 issue: 5 year: 2014 ident: 2021112516212598700_B33 article-title: Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV publication-title: J Clin Oncol. doi: 10.1200/JCO.2013.49.9020 – volume: 94 start-page: 346 issue: 3 year: 2019 ident: 2021112516212598700_B3 article-title: Treatment-free remission with first- and second-generation tyrosine kinase inhibitors publication-title: Am J Hematol. doi: 10.1002/ajh.25342 – year: 2020 ident: 2021112516212598700_B20 article-title: Bosulif (bosutinib) – volume: 15 start-page: 323 issue: 6 year: 2015 ident: 2021112516212598700_B9 article-title: Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm publication-title: Clin Lymphoma Myeloma Leuk. doi: 10.1016/j.clml.2015.03.006 – volume: 61 start-page: 8120 issue: 18 year: 2018 ident: 2021112516212598700_B15 article-title: Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1 publication-title: J Med Chem. doi: 10.1021/acs.jmedchem.8b01040 – volume: 10 start-page: 2040620719826444 year: 2019 ident: 2021112516212598700_B23 article-title: Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia publication-title: Ther Adv Hematol. doi: 10.1177/2040620719826444 – volume: 99 start-page: 458 issue: 3 year: 2014 ident: 2021112516212598700_B32 article-title: Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy publication-title: Haematologica. doi: 10.3324/haematol.2013.095158 – volume: 34 start-page: 2125 issue: 8 year: 2020 ident: 2021112516212598700_B31 article-title: Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study publication-title: Leukemia. doi: 10.1038/s41375-020-0915-9 – volume: 89 start-page: 732 issue: 7 year: 2014 ident: 2021112516212598700_B25 article-title: Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: minimum 24-month follow-up publication-title: Am J Hematol. doi: 10.1002/ajh.23728 – volume: 132 start-page: 393 issue: 4 year: 2018 ident: 2021112516212598700_B14 article-title: Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial publication-title: Blood. doi: 10.1182/blood-2016-09-739086 – volume: 122 start-page: 872 issue: 6 year: 2013 ident: 2021112516212598700_B24 article-title: European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 publication-title: Blood. doi: 10.1182/blood-2013-05-501569 – volume: 90 start-page: 429 issue: 5 year: 2015 ident: 2021112516212598700_B26 article-title: Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program publication-title: Am J Hematol. doi: 10.1002/ajh.23973 – volume: 34 start-page: 1495 issue: 6 year: 2020 ident: 2021112516212598700_B10 article-title: Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors publication-title: Leukemia. doi: 10.1038/s41375-020-0842-9 – volume: 31 start-page: 2398 issue: 11 year: 2017 ident: 2021112516212598700_B27 article-title: Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants publication-title: Leukemia. doi: 10.1038/leu.2017.253 – volume: 27 start-page: 107 issue: 1 year: 2013 ident: 2021112516212598700_B30 article-title: Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study publication-title: Leukemia. doi: 10.1038/leu.2012.181 – volume: 29 start-page: 1823 issue: 9 year: 2015 ident: 2021112516212598700_B28 article-title: Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib publication-title: Leukemia. doi: 10.1038/leu.2015.152 – year: 2020 ident: 2021112516212598700_B21 article-title: Bosulif (bosutinib) [summary of product characteristics]. – volume: 2 start-page: e186 issue: 5 year: 2015 ident: 2021112516212598700_B5 article-title: Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials publication-title: Lancet Haematol. doi: 10.1016/S2352-3026(15)00048-4 – volume: 381 start-page: 2315 issue: 24 year: 2019 ident: 2021112516212598700_B18 article-title: Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure publication-title: N Engl J Med. doi: 10.1056/NEJMoa1902328 – volume: 72 start-page: 4890 issue: 19 year: 2012 ident: 2021112516212598700_B19 article-title: The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-12-1276 – ident: 2021112516212598700_B8 article-title: NCCN: Clinical Practice Guidelines in Oncology – volume: 543 start-page: 733 issue: 7647 year: 2017 ident: 2021112516212598700_B16 article-title: The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1 publication-title: Nature. doi: 10.1038/nature21702 – volume: 30 start-page: 3486 issue: 28 year: 2012 ident: 2021112516212598700_B35 article-title: Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial publication-title: J Clin Oncol. doi: 10.1200/JCO.2011.38.7522 – volume: 91 start-page: 869 issue: 9 year: 2016 ident: 2021112516212598700_B29 article-title: Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034 publication-title: Am J Hematol. doi: 10.1002/ajh.24423 – volume: 36 start-page: 231 issue: 3 year: 2018 ident: 2021112516212598700_B34 article-title: Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE Trial publication-title: J Clin Oncol. doi: 10.1200/JCO.2017.74.7162 – volume: 31 start-page: 589 issue: 4 year: 2017 ident: 2021112516212598700_B7 article-title: Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors publication-title: Hematol Oncol Clin North Am. doi: 10.1016/j.hoc.2017.04.007 – volume: 98 start-page: 106458 year: 2020 ident: 2021112516212598700_B17 article-title: The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase publication-title: Leuk Res. doi: 10.1016/j.leukres.2020.106458 – volume: 36 start-page: 431 issue: 4 year: 2019 ident: 2021112516212598700_B36 article-title: Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants publication-title: Cancer Cell. doi: 10.1016/j.ccell.2019.08.004 – reference: 34821938 - Blood. 2021 Nov 25;138(21):2009-2010 |
| SSID | ssj0014325 |
| Score | 2.6920865 |
| Snippet | Patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant/intolerant to ≥2 tyrosine kinase inhibitors (TKIs) are at high risk of experiencing... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2031 |
| SubjectTerms | Adult Aged Aged, 80 and over Aniline Compounds - adverse effects Aniline Compounds - therapeutic use Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Female Humans Leukemia, Myeloid, Chronic-Phase - drug therapy Male Middle Aged Niacinamide - adverse effects Niacinamide - analogs & derivatives Niacinamide - therapeutic use Nitriles - adverse effects Nitriles - therapeutic use Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Pyrazoles - adverse effects Pyrazoles - therapeutic use Quinolines - adverse effects Quinolines - therapeutic use Treatment Outcome Young Adult |
| Title | A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs |
| URI | https://dx.doi.org/10.1182/blood.2020009984 https://www.ncbi.nlm.nih.gov/pubmed/34407542 https://www.proquest.com/docview/2562831044 |
| Volume | 138 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZZxy4vY0t36W5oMAYj8WpbjiM_pqWlW-NugwSyJyPJMjFL7BC7Leuv35HkS7q1pduLMUI2It8X6Rx_54LQeyeOh4wmwhpwKi0gRWIFwg8szlxf8oBTR6rvHeGJfzT1vswGs07nfDO7pOSfxMWVeSX_gyqMAa4qS_YfkG1eCgNwD_jCFRCG660wHvVWcziFekT9UKoPlgWYGtkdjqA4X6YXYE8Wdd1oBsedKiWiJRgGxuAo_NZLs3nK09J47WdFj-cFrBgm6XzAcFx1EXdV4LoKyu2t1incTo4_F5cE4UXVdV6rN0Z-N1KSXKzmG-J9yKrUmipgv9Wl9uCMUkmbusmUikRZNEdGmGZsqYd_wPJ-ys1vFa6jkvZMXnO9vap62LZrlBh5xVi9JxO6QT6TQ11vsbY5Nv7e-6mqJavj_cHvd7Xxa9rPXS6zffI1OpyOx9HkYDa5g-664F-o1hfH31v5ySO6W2-ztFrfpu7un--_zp65zl_RdsvkMXpUORx4ZNjzBHVk1kXbo4yV-fIX_oB1CLDWVrro3l5992C_bgTYRffDKv5iG52PsGYcJn3c8q2PW7ZhzTacJ7hhWx8zrLmGG6718VmBG6bBOAamYc007OJ8jRXTsGYaVkx7iqaHB5P9I6tq3WEJb0BLS5DAEz4XJB4OWUwCESRCCF_6ARsEDuHcETJgQwbmJgUbOqGwK4Cxyew4kLbnSfIMbWV5Jl8gzDgdCEZd1UnWk4Kqkot2zH1qgy_uEG8H7dYARKKqa6_aqywi7d9SN9KQRS1kO-hj88TK1HS5YS6pMY0qm9TYmhHQ7oan3tXwRwCW0uBYJvPTIgIPw1W9_TyY89zwolkD8TxbNaR-eYunX6GH7R_sNdoq16fyDZjHJX-rqfwbMIu0XA |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+phase+3%2C+open-label%2C+randomized+study+of+asciminib%2C+a+STAMP+inhibitor%2C+vs+bosutinib+in+CML+after+2+or+more+prior+TKIs&rft.jtitle=Blood&rft.au=R%C3%A9a%2C+Delphine&rft.au=Mauro%2C+Michael+J&rft.au=Boquimpani%2C+Carla&rft.au=Minami%2C+Yosuke&rft.date=2021-11-25&rft.issn=1528-0020&rft.eissn=1528-0020&rft.volume=138&rft.issue=21&rft.spage=2031&rft_id=info:doi/10.1182%2Fblood.2020009984&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-4971&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-4971&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-4971&client=summon |